MedTrace Logo

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

NCT03693378 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1349

Last updated 2022-03-31

No results posted yet for this study

Summary

PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care imaging.

Conditions

Sponsors & Collaborators

  • Immunovia, Inc.

    lead INDUSTRY

Principal Investigators

  • Rolf Ehrnström · Immunovia, Inc.

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-19
Primary Completion
2021-11-12
Completion
2021-11-12

Countries

  • United States
  • Canada
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03693378 on ClinicalTrials.gov